Quantcast

Posts related to ‘Biotech’

What’s A Better Buyout: Ardea or Amylin? (RDEA, AMLN, AZN, BMY, MRK)

Posted: April 23, 2012 at 2:54 pm

Ardea Biosciences, Inc. (NASDAQ: RDEA) is soaring today on news that AstraZeneca PLC (NYSE: AZN) is paying about $1.26 billion to acquire the company.  With another small-cap to mid-cap biotech and ...
Read Full Story »

Key Biotech Issues To Watch (XBI, ANIK, BCRX, CBST, DNDN, GILD, ILMN, TRGT)

Posted: April 18, 2012 at 8:23 am

Biotech is a sector which is often mixed with a hodge-podge of winners and losers based on news flow from analysts and/or key drug developments which often have very little to ...
Read Full Story »

Options Traders Extending Out to September in VIVUS (VVUS)

Posted: April 10, 2012 at 12:11 pm

VIVUS Inc. (NASDAQ: VVUS) was trying to recover this morning and briefly spent some time in positive territory after an obvious concern for shareholders that the FDA is not quite ...
Read Full Story »

VioPharma Runs Into FDA & FTC Troubles Over Staph Drug (VPHM)

Posted: April 10, 2012 at 8:35 am

ViroPharma Incorporated (NASDAQ: VPHM) is getting crushed on news that the Food & Drug Administration has denied the petition filed by ViroPharma on March 17, 2006 related to the FDA's ...
Read Full Story »

VIVUS Faces Shareholder Risks After FDA Delay On Obesity Pill (VVUS, ARNA, OREX)

Posted: April 10, 2012 at 7:11 am

VIVUS Inc. (NASDAQ: VVUS) is getting a bit of a haircut this morning on the heels of some news from the Food & Drug Administration which may throw up some ...
Read Full Story »

Drug Maker Prices Secondary Offering (GALE)

Posted: April 5, 2012 at 10:11 am

Biotech firm Galena Biopharma Inc. (NASDAQ: GALE) this morning priced a secondary offering of 8.5 million shares at $1.50/share, a discount of nearly 20% to last night’s closing price of ...
Read Full Story »

Abbott’s Hep-C Pressures All Hep-C Rivals (ABT, RIGL, GILD, VRTX, IDIX)

Posted: April 4, 2012 at 1:28 pm

News from Abbott Laboratories (NYSE: ABT) on its positive Phase II study results from two different interferon-free hepatitis C treatment has the entire drug sector up in arms as it ...
Read Full Story »

Pacific Biosciences Files to Raise Capital (PACB)

Posted: April 3, 2012 at 1:10 pm

Pacific Biosciences of California, Inc. (NASDAQ: PACB) has just filed paperwork with the Securities and Exchange Commission to raise up to $150 million in a mixed securities shelf registration statement.  ...
Read Full Story »

Astex Gets on the Map (ASTX)

Posted: April 3, 2012 at 8:24 am

Astex Pharmaceuticals, Inc. (NASDAQ: ASTX) is the NASDAQ pre-market leader this morning on news that its subcutaneous SGI-110 interim phase I.II MDS and AML data demonstrated differentiated PK profile and ...
Read Full Story »

Stemline Therapeutics Files for IPO (STML)

Posted: April 2, 2012 at 4:09 pm

Stemline Therapeutics, Inc. has just filed its paperwork with the Securities and Exchange Commission that will allow it to conduct an initial public offering. The company will list is shares under ...
Read Full Story »

Neostem Pounds Holders In Capital Raise (NBS)

Posted: March 29, 2012 at 10:41 am

If there is one sector you can count on to raise capital either after opportunistic share price gains or at the worst prices seen in years it is the emerging ...
Read Full Story »

Potential Deathblow for Chelsea (CHTP)

Posted: March 29, 2012 at 9:20 am

Chelsea Therapeutics International Ltd. (NASDAQ: CHTP) is being beaten hard this morning.  News hit that the FDA has now rejected the company's Northera drug to treat low blood pressure for ...
Read Full Story »

The Inevitable Amylin Buyout (AMLN, BMY, LLY, ALKS)

Posted: March 28, 2012 at 9:52 am

If there was a merger candidate which ever made sense in biotech and pharma it is Amylin Pharmaceuticals, Inc. (NASDAQ: AMLN).  News from Bloomberg is out that the company has rejected an ...
Read Full Story »

Diabetes Drug Approved For Europe (AMLN, LLY)

Posted: March 23, 2012 at 8:49 am

Amylin Pharmaceuticals Inc. (NASDAQ: AMLN) and Eli Lilly & Co. (NYSE: LLY) are in the news on the diabetes front.  The companies have announced that the European Commission has now ...
Read Full Story »

Durata Therapeutics Files For IPO (DRTX)

Posted: March 22, 2012 at 3:59 pm

A company called Durata Therapeutics, Inc. has filed to come public via an initial public offering.  While no terms have been set, the paperwork filed at the Securities and Exchange Commission ...
Read Full Story »